Teriparatide biosimilar - Stelis Biopharma

Drug Profile

Teriparatide biosimilar - Stelis Biopharma

Alternative Names: SBL 001

Latest Information Update: 17 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Stelis Biopharma
  • Class Osteoporosis therapies; Peptide hormones; Skin disorder therapies
  • Mechanism of Action Bone resorption factor inhibitors; Osteogenesis stimulants; Parathyroid hormone receptor type 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Osteoporosis

Most Recent Events

  • 17 Jan 2018 Stelis Biopharma plans to launch teriparatide biosimilar worldwide, in 2019 (Stelis Biopharma pipeline, January 2018)
  • 17 Jan 2018 Stelis Biopharma plans a phase I trial in Osteoporosis (In volunteers) in Australia (ACTRN12618000013268p) (Trial profile 700292268)
  • 01 Dec 2017 Preclinical trials in Osteoporosis in Australia (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top